OBJECTIVES:  Identify and measure direct medical, non-medical and indirect costs related to Hepatitis C and associated conditions in Brazil. METHODS:  The costs of hepatitis C and associated conditions were estimated using the base year 2014. The perspective of the Unified Health System (SUS) and that of society was adopted. The data were obtained from universal access information systems provided by the Ministry of Health. Direct medical, non-medical and indirect direct costs were evaluated using the macro-costing methodology for each of the clinical conditions identified through the International Classification of Diseases (ICD 10). RESULTS:  The estimated total medical direct cost of the different stages of HCV infection accounted for more than 399 million reais in 2014. Chronic hepatitis C, liver transplantation and liver fibrosis and cirrhosis were responsible for the largest portions of this amount, respectively 86.9, 12.1 and 0.6% of total direct medical costs. The non-medical direct cost, for all clinical conditions (CID), accounted for more than 1,400,000 reais. Where transport costs of patients and caregivers in chronic hepatitis C accounted for 69.4% of this value. The estimated total cost for the indirect cost of hepatitis C and associated conditions was over 6 million reais in 2014. The clinical condition responsible for 50% of this value was liver fibrosis and cirrhosis. CONCLUSIONS:  This study allowed to show the economic impact of hepatitis C and associated conditions in Brazil, from the perspective of the Unified Health System and that of society. Health expenditures and losses evidenced the need for actions aimed at the prevention of HCV infection, as well as policies to reduce the price of antivirals; Which may be important strategies to reduce the consumption of resources in this reality. Both those used by the health service to defray the various actions and services, as well as the expenses or lost by society.